Genomic aberrations of thePTENtumour suppressor are among the most common in prostate cancer. In this Review, the authors describe the roles of PTEN, consider how PTEN status could act as a potential prognostic and predictive biomarker, and discuss the potential of PTEN and its downstream pathways as a therapeutic target.
- Tamara Jamaspishvili
- David M. Berman
- Tamara L. Lotan